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1  | INTRODUC TION
Hepatocellular carcinoma (HCC) is the fourth-leading cause of can-
cer death worldwide.1 In contrast to trends with other common ma-
lignancies, HCC incidence and mortality are increasing in the United 
States, largely because of an increase in non-alcoholic fatty liver dis-
ease and peak in hepatitis C virus-related cirrhosis.2-4 Unfortunately, 
HCC prognosis is poor with median survival under 2 years after diag-
nosis, which in part can be attributed to underuse of early detection 
strategies and limited effectiveness of therapies for patients with 
advanced stage disease.5
Several professional societal guidelines recommend HCC sur-
veillance in at-risk populations, including those with cirrhosis, 
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Abstract
Background/Aims: Semiannual hepatocellular carcinoma (HCC) surveillance is rec-
ommended in patients with cirrhosis; however, recent studies have raised questions 
over its utility. We investigated the impact of surveillance on early detection and 
survival in a nationally representative database.
Methods: We included patients with cirrhosis and HCC from the Optum database 
(2001-2015) with >6 months of follow-up between cirrhosis and HCC diagnoses. 
Surveillance adherence was defined as proportion of time covered (PTC), with each 
6-month period after abdominal imaging defined as ‘covered’. To determine the as-
sociation between surveillance and mortality, we compared PTC between fatal and 
non-fatal HCC.
Results: Of 1001 patients with cirrhosis and HCC, 256 died with median follow-up 
30 months. Median PTC by any imaging was greater in early-stage vs late-stage HCC 
(43.6% vs 37.4%, P = .003) and non-fatal vs fatal HCC (40.8% vs 34.3%, P = .001). In 
multivariable analyses, each 10% increase in PTC was associated with increased early 
HCC detection (OR 1.07, 95% CI 1.01-1.12) and decreased mortality (HR 0.95; 95% CI 
0.90-1.00). On subgroup analysis, PTC by CT/MRI was associated with early tumour 
detection and decreased mortality; however, PTC by ultrasound was only associated 
with early detection but not decreased mortality. These findings were robust across 
sensitivity analyses.
Conclusions: In a US cohort of privately insured HCC patients, PTC by any imag-
ing modality was associated with increased early detection and decreased mortality. 
Continued evaluation of HCC surveillance strategies and effectiveness is warranted.
K E Y W O R D S
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using ultrasound (US) with or without alpha-foetoprotein (AFP).6-8 
However, HCC surveillance in patients with cirrhosis does not have 
level I evidence and has been primarily supported by cohort studies 
demonstrating an association with earlier stage detection, greater 
likelihood of receiving curative therapy and improved survival.9-11 
These studies have notable limitations including potential for lead-
time bias, length time bias and residual confounding.12 It is well 
recognized that US and AFP can have limited sensitivity for early 
stage HCC detection in clinical practice, with a recent meta-analysis 
reporting a sensitivity of only 63% for early-stage HCC detection 
when using the two tests in combination.13 Studies have also sug-
gested high rates of false positive or indeterminate results leading 
to potential screening-related harms, such as additional diagnostic 
imaging and/or biopsy.14,15 Other limitations of surveillance include 
poor surveillance adherence and appropriate treatment for HCC 
patients detected at an early stage, related to both physician and 
patient factors.16,17 These prevalent failures in the HCC screening 
process have led to increasing controversy about the value of sur-
veillance in patients with cirrhosis.18
This controversy was recently brought to light after a case-con-
trol study from the Veterans Affairs system failed to show an im-
provement in overall survival with HCC surveillance.12 The authors 
of this study found no difference in surveillance receipt between pa-
tients with fatal HCC and a matched cohort of patients with cirrho-
sis. However, it remains unclear if these results are generalizable to a 
non-Veterans Affairs population and warrant validation, particularly 
as prior studies have suggested large site-level and physician-level 
variations in HCC surveillance receipt and effectiveness.
Therefore, we aimed to characterize the association between 
HCC surveillance receipt and overall survival in a large nationally 
representative cohort of privately insured patients with cirrhosis.
2  | METHODS
2.1 | Cohort
We conducted a secondary analysis of the Optum database (2001-
2015), a claims database including over 150 million privately-insured 
patients in the United States. We included patients with cirrhosis, 
defined by ≥2 previously validated ICD-9 codes19 and HCC (≥2 ICD-9 
codes of 155.0 or 155.2). We required two ICD-9 codes for cirrhosis 
and HCC to maximize the positive predictive value for both condi-
tions. Exclusion criteria included any extrahepatic cancer diagnoses 
other than non-melanoma skin cancer, history of liver transplanta-
tion prior to first HCC diagnosis, and <6 months of follow-up be-
tween cirrhosis diagnosis and HCC diagnosis (Figure 1).
2.2 | Definitions
We classified cirrhosis as compensated or decompensated, with 
decompensated cirrhosis diagnosis based on a history of ascites, 
hepatic encephalopathy, or variceal bleeding. Ascites was diagnosed 
based on relevant diagnosis codes, plus use of diuretics (loop diuret-
ics and/or mineralocorticoid receptor antagonists), receipt of para-
centesis, or receipt of transjugular intrahepatic portosystemic shunt 
placement. Hepatic encephalopathy was diagnosed using relevant 
diagnosis codes plus use of lactulose or rifaximin. Disease aetiology 
was based on diagnosis codes: viral disease was defined as the pres-
ence of at least two diagnostic codes for chronic hepatitis B or C in-
fection, alcoholic liver disease based on the presence of at least two 
codes for alcohol misuse, combined alcoholic and viral disease based 
on the presence of at least two codes for both viral hepatitis and 
alcoholic liver disease, and non-viral non-alcoholic disease based on 
one or no codes for either viral or alcoholic liver disease. Diagnostic 
and procedure codes are summarized in Table S1.
2.3 | Adherence to surveillance
Adherence to surveillance was measured by the proportion of time 
‘covered’ (PTC), that is time up-to-date with HCC surveillance.20 
Each 6-month period after abdominal imaging including US, con-
trast-enhanced CT and contrast-enhanced MRI was defined as 
‘covered’. All imaging studies could have been done with or without 
AFP, but the presence of AFP was not sufficient when used alone 
given insufficient sensitivity for early HCC detection. Although im-
aging studies may not have been conducted for diagnostic purposes, 
we considered patients covered after any adequate study because 
these studies obviated the need for repeat surveillance testing; how-
ever, we did not include studies which were inadequate for diagnosis 
or surveillance such as Doppler US or non-contrast-enhanced cross-
sectional imaging. PTC was measured as time up-to-date, divided by 
the total follow-up period between date of the first cirrhosis diag-
nosis code and the date of HCC diagnosis. We excluded the time 
frame between any CT or MRI obtained within six months of HCC 
diagnosis from the PTC numerator and denominator to adjust for 
delays between HCC diagnosis on imaging and placement of HCC 
diagnostic codes.
Keypoints
Liver cancer is a major cause of cancer-related death. 
Patients with cirrhosis are at high risk for developing liver 
cancer. While screening for liver cancer among patients 
with cirrhosis is recommended, there has been controversy 
recently about how useful screening use. Here, we used a 
large insurance claims database with >150 000 000 peo-
ple to investigate whether prior liver cancer screening im-
proves outcomes in patients with cirrhosis and liver cancer. 
We found that liver cancer screening is associated with im-
proved survival and detection of cancer at an early stage.
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2.4 | Statistical analysis
Continuous variables were depicted as mean ± standard deviation 
or median (interquartile range [IQR]), and categorical variables were 
represented as proportions (%). Normally distributed variables were 
compared using t tests and non-normally distributed variables were 
compared using the rank-sum test. Chi-square tests were used to 
compare categorical variables.
The primary outcome of our study was the association between 
PTC and patient survival and a secondary outcome was the associ-
ation between PTC and early stage HCC detection facilitating cu-
rative treatment receipt. For the association between survival and 
PTC, we used three methods. First, we used a Wilcoxon rank-sum 
test to compare PTC based on survival status as a binary variable 
(ie deceased or alive). Next, we performed multivariable logistic 
regression to compare adjusted PTC (adjusted for age, sex, race, 
region, cirrhosis diagnosis year, decompensated liver disease at 
cirrhosis diagnosis and disease aetiology) based on survival status. 
Finally, we used a Cox proportional hazards model based on time-to-
event analysis; patients were censored at loss to follow-up or liver 
transplantation. In the multivariable Cox model, PTC was the pri-
mary independent variable; covariates were age, sex and all other 
non-redundant factors associated with mortality at P < .10 in uni-
variable analyses. We also performed sensitivity analysis with ad-
justment for lead-time bias by assuming sojourns of 3, 6 or 9 months 
in patients who had PTC below the median.10
In a secondary analysis, we also performed multivariable logistic 
regression to define correlates of curative treatment receipt, defined 
as receiving liver transplantation, surgical resection or local ablation 
as the first HCC treatment. For this analysis, PTC was the primary 
independent variable; covariates were age, sex and all other non-re-
dundant factors associated with early-stage diagnosis at P < .10 in 
univariable analyses.
For both analyses, we first defined PTC using receipt of any 
imaging (US, contrast CT or contrast MRI). We then performed 
subgroup analyses to assess association between PTC and both 
outcomes among (1) those who received abdominal US and (2) 
those who received contrast-enhanced CT or MRI. Finally, we 
performed several sensitivity analyses: (1) requiring either 9 or 
12 months of follow-up between cirrhosis and HCC diagnoses, (2) 
excluding patients with decompensated cirrhosis and (3) excluding 
inpatient imaging studies.
For all analyses, statistical significance was defined as a two-
tailed P < .05. All statistical analyses were performed using R version 
F I G U R E  1   Study design
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3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) with 
the tidyverse,21 survival22 and survminer23 packages.
3  | RESULTS
3.1 | Patient characteristics
We identified 171 242 individuals with cirrhosis, of whom 1001 had 
HCC (Figure 1). Among those with HCC, 256 died during follow-up. 
Median time between cirrhosis and HCC diagnoses was 37.3 months 
(IQR 20.9-62.0 months) and median follow-up after HCC diagnosis 
was 30.4 months (IQR 12.8-49.7 months). The aetiology of disease 
was combined alcoholic and viral disease in 42%, viral disease alone in 
28%, alcoholic liver disease alone in 17% and non-viral non-alcoholic in 
13%. Approximately 57% and 24% of patients with chronic hepatitis B 
or C, respectively, received antiviral therapy during follow-up. Among 
patients with HCC who died during follow-up, median survival was 
9.4 months (IQR 3.0-22.1 months). Patients with fatal HCC were older, 
more frequently had history of alcohol use, and were less frequently 
from the Pacific region of the United States than those with non-fatal 
HCC (Table 1). Prior to HCC diagnosis, most patients (54%) had imaging 
using a combination of US, CT and MRI; 28% had imaging exclusively 
with US; 11% of patients exclusively with CT/MRI; and 8% of patients 
had not received any surveillance prior to HCC diagnosis.
3.2 | Proportion time covered
Overall median PTC by any abdominal imaging was 38.7%, by US 
13.1% and by CT or MRI 25.2%. Factors associated with higher 
PTC included younger age, Asian race, region, later year of cir-
rhosis diagnosis, subspecialty hepatology care, combined viral-
alcohol disease aetiology and history of hepatic decompensation 
(Tables S2–S4).
3.3 | Survival analysis
On primary analysis, PTC by any imaging was higher in patients with 
non-fatal HCC than fatal HCC: 40.8% vs 34.4%, P = .001 (Table 2). 
On subgroup analysis, PTC by CT/MRI was significantly higher in 
patients with non-fatal HCC, but PTC by US alone did not differ 
between fatal and non-fatal HCC (Table 2). Results were consistent 
across sensitivity analyses as detailed in Table 2.
In adjusted analysis, there was no difference in PTC by any im-
aging or PTC by US between fatal and non-fatal HCC (Table S5). 
However, PTC by CT/MRI was significantly higher among patients 
with non-fatal than fatal HCC (difference = −4.9%; 95% confidence 
interval −8.9 to −1.0%; P = .015). The association between survival 
and adjusted PTC by CT/MRI remained significant across most sen-
sitivity analyses except among those with compensated cirrhosis 
(Table S5).
3.4 | Predictors of survival
On univariable Cox analysis, greater PTC by any modality was 
associated with decreased mortality: hazard ratios (HR) per 10% 
change in PTC were 0.91 (95% CI 0.87-0.95) for any imaging, 0.95 
(0.90-0.99) for US and 0.90 (0.85-0.95) for CT/MRI (Figure 2; 
Table 3). After adjustment for lead-time bias, the association be-
tween any imaging and decreased mortality remained significant 
(Figure S1). In multivariable Cox analysis (Methods and Table S6), 
adjusted PTC by any imaging remained significantly associated 
with survival (HR 0.94; 95% CI 0.90-0.99 per 10% change in PTC) 
(Table 3). In subgroup analysis, PTC by CT or MRI but not US was 
associated with survival (Table 3). On sensitivity analysis where 
only outpatient imaging studies were included, adjusted PTC by 
any imaging or US was not significantly associated with survival, 
whereas PTC by CT/MRI remained significant (Table S7). When 
stratified by modality, adjusted PTC by MRI alone was associated 
with decreased mortality (HR 0.69, 0.52-0.93, P = .01), but not PTC 
by CT (HR 0.92, 0.85-1.00, P = .06).
3.5 | Early diagnosis and multivariable analysis
We used receipt of curative therapy (ablation, resection or liver 
transplantation) as a proxy for early HCC diagnosis. Patients with 
early stage HCC who underwent curative treatment had higher 
PTC by any imaging compared to those with later-stage HCC 
(43.6% vs 37.4%, P = .003) (Table S8), which was consistent across 
sensitivity analyses. On subgroup analysis, PTC by CT/MRI was 
also greater in patients with early-stage HCC who underwent cu-
rative treatment; however, there was no difference in PTC by US 
except in a sensitivity analysis among those with compensated cir-
rhosis (Table S8).
In univariable logistic regression, PTC by any imaging was as-
sociated with increased probability of early detection and curative 
treatment receipt: OR 1.08 (1.03-1.14), P = .001 (Table 4). After 
adjustment for other factors associated with early-stage diagno-
sis (Table S9), PTC by any imaging or CT/MRI but not by US were 
associated with early detection and curative treatment receipt 
(Table 4). Some patients with early-stage disease may have received 
no therapy or only locoregional therapy. We conducted sensitivity 
analyses to account for this possibility by assuming that (in addition 
to patients receiving curative therapy) 20% of patients receiving 
locoregional therapy, no therapy or either locoregional therapy or 
no therapy had early-stage disease. PTC by any imaging remained 
significantly associated with increased early diagnosis in univariable 
analysis and most multivariable analyses (Table S10).
4  | DISCUSSION
In a large privately insured cohort of patients with HCC, PTC by 
any imaging was associated with decreased mortality and increased 
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early HCC detection on both unadjusted and adjusted analyses. On 
subgroup analysis based on imaging type, unadjusted and adjusted 
PTC by CT/MRI were associated with early diagnosis and decreased 
mortality. While unadjusted PTC by US was associated with early 
diagnosis and decreased mortality, the association was no longer sig-
nificant in multivariable models.
This study adds to the literature about HCC surveillance util-
ity by suggesting that surveillance is beneficial. Our study results 
and methodology differ from the recent Veterans Affair study 
by Moon et al in several ways.12 Our definition of surveillance is 
continuous and accounts for differences in frequency of imaging 
studies. In order to be effective, surveillance should be conducted 
at regular intervals, and a single imaging study does not consti-
tute surveillance.6 In contrast, the Moon et al study did not clearly 
define surveillance frequency, but rather reported the proportion 
of patients undergoing imaging within a prolonged period of up 
to 4 years. It also included AFP-only surveillance which has not 
been shown to be an effective surveillance strategy. In addition, 
our study used far less restrictive criteria for follow-up duration 
before HCC diagnosis, which is less likely to yield a biased cohort. 
TA B L E  1   Characteristics of patients with fatal and non-fatal hepatocellular carcinoma
Trait Overall Fatal (N = 256) Non-fatal (N = 745) P value
Age 58.4 ± 10.6 60.9 ± 10.5 57.5 ± 10.5 <.001
Year of HCC diagnosis 2012 (2009-2013) 2010 (2008-2013) 2012 (2010-2014) <.001
% Male 67.6% 70.7% 66.6% <.001
Race
Asian 6.6% 3.9% 7.5% .057
Black 7.4% 9.8% 6.6%
Hispanic 17.9% 15.2% 18.8%
White 61.2% 65.4% 59.9%
Other/unknown 6.9% 5.9% 7.2%
Subspecialty care before cancer diagnosis
Gastroenterologist 89.7% 91.0% 89.3% .41
Hepatology (subset of 
gastroenterologists)
29.3% 23.1% 31.4% .011
Number of imaging studies before cancer diagnosis
Ultrasound 2 (1-4) 2 (1-4) 2 (1-5) .88
Computed tomography 1 (0-3) 2 (1-3) 1 (0-2) .004
Magnetic resonance imaging 0 (0-2) 0 (0-1) 0 (0-2) .006
Computed tomography or magnetic 
resonance imaging
2 (1-4) 2 (1-4) 2 (1-4) .57
Any imaging 5 (3-9) 5 (3-8) 5 (2-9) .84
Region
Mountain 4.0% 4.7% 3.8% .003
Midwest 16.5% 19.9% 15.3%
Northeast 7.1% 8.2% 6.7%
Pacific 17.8% 9.8% 20.5%
Southeast 34.2% 38.3% 32.8%
Southwest 20.5% 19.1% 20.9%
Hepatitis C virus 67.3% 64.1% 68.5% .20
Hepatitis B virus 14.3% 9.8% 15.8% .017
Alcohol history 59.0% 69.9% 55.3% <.001
Complications at cirrhosis diagnosis
Ascites 6.7% 4.7% 7.4% .10
Encephalopathy 2.7% 3.5% 2.4% .39
Variceal bleed 8.3% 8.6% 8.2% .84
Any decompensation 15.4% 15.2% 15.4% .94
Alpha-foetoprotein measurement 62.3% 52.9% 65.5% <.001
Note: Bold font indicates statistical significance.
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Finally, the cohort in our study is more representative of the over-
all HCC population than that in the Veterans Affairs study in which 
no patients with fatal HCC underwent liver transplantation and 
<17% received curative therapy.
Subgroup analyses showed that while PTC by CT/MRI was 
consistently associated with both improved survival and early di-
agnosis, PTC by US was only consistently associated with early 
diagnosis. There are several possible explanations for the lack of 
association between PTC by US and survival. First, US may lack 
sufficient sensitivity for early stage disease detection: US sensi-
tivity is decreased by obesity, liver nodularity or severe steatosis, 
which are common features in Western patients with cirrhosis.9,13 
This is especially notable given that combined use of US and AFP 
was low in the Optum database with median 0% PTC by US plus 
AFP in the overall cohort. Second, there may be a ‘threshold’ PTC 
by US that is adequate for identifying early-stage vs intermedi-
ate-stage disease, and if that threshold is not reached then the 
benefit of US surveillance is not significant. Randomized studies 
TA B L E  2   Comparison of proportion of time covered between fatal and non-fatal hepatocellular carcinoma
Period between cirrhosis and HCC 
diagnosis Proportion time covered by Fatal HCC Non-fatal HCC P value
>6 months
All patients
N = 745 (non-fatal), N = 256 (fatal)
Any imaging 34.3% (16.7%-52.1%) 40.8% (19.1%-64.6%) .001
Ultrasound 21.4% (7.2%-43.7%) 27.0% (6.9%-49.7%) .161
Computed tomography or 
magnetic resonance imaging
11.6% (0%-27.9%) 14.7% (0%-42.9%) .030
>9 months
All patients
N = 692 (non-fatal), N = 240 (fatal)
Any imaging 32.3% (16.0%-49.1%) 40.4% (19.4%-62.4%) <.001
Ultrasound 20.3% (6.8%-39.3%) 26.1% (7.4%-47.0%) .050
Computed tomography or 
magnetic resonance imaging
11.6% (0%-27.1%) 15.1% (0%-41.9%) .005
>12 months
All patients
N = 646 (non-fatal), N = 228 (fatal)
Any imaging 31.6% (15.7%-47.9%) 39.4% (19.2%-62.1%) <.001
Ultrasound 19.8% (7.0%-38.5%) 25.4% (7.7%-45.1%) .060
Computed tomography or 
magnetic resonance imaging
11.7% (0%-26.3%) 15.2% (0%-39.8%) .005
>6 months, excluding those with 
decompensated cirrhosis
N = 630 (non-fatal), N = 217 (fatal)
Any imaging 32.1% (15.5%-49.0%) 38.8% (17.1%-61.8%) .003
Ultrasound 19.8% (5.8%-42.0%) 24.2% (5.6%-46.9%) .24
Computed tomography or 
magnetic resonance imaging
11.3% (0%-27.7%) 12.6% (0%-40.2%) .14
Note: Bold font indicates statistical significance.
Abbreviation: HCC, hepatocellular carcinoma.
F I G U R E  2   Survival based on proportion time covered by surveillance. Kaplan-Meier curves depicting survival based on proportion time 
covered by (A) any imaging, (B) ultrasound (US) or (C) computed tomography (CT) or magnetic resonance imaging (MRI)
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suggest that short HCC surveillance intervals (3-4 months) are 
required to achieve greater detection of very early-stage vs ear-
ly-stage HCC,24,25 and perhaps an analogous threshold exists be-
tween early- and intermediate-stage HCC. While the distinction 
between very early- and early-stage HCC is important,26 the dis-
tinction between early- and intermediate-stage disease may be 
more meaningful as patients with intermediate-stage disease are 
frequently ineligible for curative therapy.27,28
CT and MRI are more considerably sensitive for HCC than 
US, but whether CT or MRI are appropriate and cost-effective as 
screening modalities is not well-established.29 A recent prospec-
tive cohort study comparing HCC surveillance by MRI vs US in 
Korean patients primarily with viral hepatitis showed superior 
HCC detection rates with MRI, although most tumours detected 
on MRI alone were very early stage.30 Cost-effectiveness analyses 
of surveillance strategies incorporating cross-sectional imaging 
have yielded mixed results.31-33 Furthermore, these analyses did 
not require inclusion of AFP in screening strategies; in our cohort, 
use of AFP was low, so we were unable to assess the association 
between AFP and prognosis or early diagnosis. Our study suggests 
that US-only surveillance may not improve prognosis and that a 
strategy incorporating CT and/or MRI may be more effective. 
However, further prospective studies on cross-sectional imaging 
for routine HCC surveillance is required to address whether this 
approach is valid.
PTC was low among individuals with HCC in our study and the 
median PTC by any imaging of 39% corresponds approximately to 
an imaging study every 15 months. This value is similar to what 
was previously reported in other analyses of commercial insurance 
claims database (ie Truven) and systematic reviews.17,20 Disparities 
in healthcare utilization and delivery exist based on race, insurance 
type, geography (eg urban vs rural) and treatment setting (eg aca-
demic vs community) among patients with HCC.34-36 In addition, pa-
tients often have misconceptions about HCC and surveillance, and 
patient-perceived barriers to HCC surveillance have been associated 
with lower HCC surveillance rates.37 Previous studies found that 
seeing a non-gastroenterology provider, greater age, compensated 
cirrhosis, non-Caucasian race and lower socioeconomic status are 
associated with decreased adherence to HCC surveillance.20,38,39 
Among patients with HCC in the Optum database, younger age, de-
compensated disease and subspecialty hepatology care were associ-
ated with increased HCC surveillance; however, it was Asian patients 
who had the highest surveillance rates.
Our study has several limitations that warrant discussion. First, 
there is a risk of confounding by indication based on imaging modal-
ity: CT or MRI may have been more frequently obtained because of 
symptoms or to follow indeterminate nodules. However, the presence 
of symptoms at HCC diagnosis is associated with a poorer prognosis,40 
and patients with higher PTC were more likely to have liver decompen-
sation (data not shown), so one would expect that this confounding by 
indication from symptomatic HCC would produce an association be-
tween greater PTC by CT/MRI and poorer prognosis. We also excluded 
CT or MRI obtained within 6 months of HCC diagnosis to account for 
delays between HCC diagnosis and diagnostic code entry, to decrease 
the risk of confounding by indication. Second, we were not able to de-
termine whether a study was obtained for surveillance or for another 
indication. We attempted to account for this by separately analysing 
outpatient studies, which are presumably more likely to be performed 
for surveillance than are inpatient or emergency department studies. 
We also note that in practice any adequate imaging study would serve 
Proportion time under 
surveillance (per 10%)
Unadjusted 
hazard ratio P value
Adjusted hazard 
ratioa P value
Any imaging 0.91 (0.87-0.95) <.001 0.94 (0.90-0.99) .026
Ultrasound 0.95 (0.90-0.99) .016 0.99 (0.94-1.04) .80
Computed tomography or 
magnetic resonance imaging
0.90 (0.85-0.95) <.001 0.92 (0.87-0.97) <.001
Note: Bold font indicates statistical significance.
aAdjusted for age, sex, race, region, year of cirrhosis diagnosis, disease aetiology and history of 
decompensation at time of cirrhosis diagnosis. Hazard ratio was not adjusted for treatment type as 
that is itself associated with proportion time under surveillance. 
TA B L E  3   Association between 
proportion time under surveillance and 
mortality





odds ratioa P value
Any imaging 1.08 (1.03-1.14) .001 1.08 
(1.03-1.13)
.002
Ultrasound only 1.05 (1.00-1.10) .033 1.04 
(1.00-1.09)
.068
Computed tomography or 
magnetic resonance imaging
1.05 (1.01-1.10) .026 1.05 
(1.00-1.10)
.030
Note: Bold font indicates statistical significance.
a Adjusted for age, sex and disease aetiology. 
TA B L E  4   Association between 
proportion time under surveillance and 
diagnosis at an early stage
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as surveillance, regardless of the original indication for the study. Third, 
we could not distinguish between prevalent and incident cirrhosis di-
agnoses, and patients with an existing cirrhosis diagnosis on entry into 
the Optum database may have undergone surveillance studies we 
could not measure. If this is the case, though, we expect that this mis-
classification would have tended to decrease the measured impact of 
surveillance. Fourth, we did not have data on tumour stage, and our use 
of receipt of curative therapy as a proxy for early diagnosis is limited 
by the possibility for disparities in healthcare delivery/access and non-
use of potentially curative treatment modalities in patients with more 
advanced liver disease. In addition, it can be difficult to determine with 
administrative databases whether treatment was administered with 
curative intent, especially with patients undergoing transarterial ther-
apy with the aim of downstaging to meet criteria for transplant.41 Our 
cohort included only a small number of patients of Asian or African an-
cestry, which is a notable limitation given the racial disparities in HCC 
care described in the previous paragraph.35,36,42 Finally, there is risk 
for ascertainment bias as patients may have lost commercial insurance 
following their HCC diagnosis, and patients who subsequently died 
may have been more likely to have lost insurance because of functional 
decline. It is unlikely this ascertainment bias would have differentially 
affected patients based on PTC under the null hypothesis of no effect 
of surveillance.
In conclusion, we found that in a large insurance claims database, 
HCC surveillance as measured by PTC by any imaging or by CT/MRI 
was associated with improved survival and diagnosis at an earlier 
stage, but PTC by abdominal US was not associated with survival. 
Our study highlights the need for further study of optimal surveil-
lance strategies for patients with cirrhosis and brings further ques-
tion to the effectiveness of US-based surveillance.
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